{"ticker": {"uuid": "6034a251-2b1a-4168-b04d-a4758bd98ac3", "symbol": "BNR", "name": "Burning Rock Biotech\u00a0Ltd", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Diagnostics & Research"}, "articles": [{"title": "Burning Rock Biotech Ltd (BNR) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Burning Rock Biotech Ltd (BNR), detailing its current price momentum score, support and resistance levels, and indicator and moving average readings. It highlights that BNR's stock is trading between resistance at 14.77 and support at", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bnr/technical", "source_name": "TradingKey", "published_at": "2026-06-19T05:09:22", "published_display": "19 Jun 2026 05:09", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Biotech Ltd (BNR) Institutional Confidence", "summary": "Burning Rock Biotech Ltd (BNR) currently has an institutional shareholding score of 3.00, placing it 56th out of 76 in the Healthcare Providers & Services industry. The institutional shareholding proportion is 45.78%, showing a 1.67% decrease quarter-over-quarter. James Simons is", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bnr/sentiment", "source_name": "TradingKey", "published_at": "2026-06-19T04:39:44", "published_display": "19 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Biotech Ltd (BNR) Financial Health: Profitability & Balance Sheet Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTFBhQTNRa3V6M0Vfcnk3R0ttN1BoeEhOOTI5Y1I2aldLbHJrQUV5YTAtekxXYXJkV09pRTQ5WjRzeURQUTYtYm8wa1Z3U0RHN2l4X0tQSFYySHN4Q0s4U0JJWXl3TnZKYkRKN3NEbDFRQ20zMllyZ2VjWg?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T16:14:40+00:00", "published_display": "18 Jun 2026 16:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Biotech Ltd (BNR) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMidkFVX3lxTE90bXFfVktURDV1MkI5RDBGVFhfZXZrbjVxRjZ6eU5OQzAya0hsUmxhVXRRZWlQcGlobk5XT3JmTHFLcEtIc0thWWF5YjEzeEpMNi1qZW5kbjROeS1hWDZUWEF6Yk9MMUYxLVBsQW9ZUmdTTGpfTHc?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T16:14:08+00:00", "published_display": "18 Jun 2026 16:14", "sentiment": "negative", "sentiment_pct": 5, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Biotech Ltd (BNR) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "", "url": "https://news.google.com/rss/articles/CBMib0FVX3lxTE9LYzNrVnZWS2VBT1RENmFEcnNWS24wblpIQTZMOEszUzY2WWlVNGEtR2RCYWlmTDdPd0czX3QyNExYQWdrUnd2bGNHRGJFOVhITG1kbXlZTWZ0eDVCT3JicmNCNl9aSGlPN0dIVkExQQ?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T20:35:26+00:00", "published_display": "17 Jun 2026 20:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Biotech Ltd (BNR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Burning Rock Biotech Ltd (BNR), detailing its financial performance by business segments and regional contributions for fiscal years 2018 and 2019. It notes that relevant data for these periods have not yet been disclosed by the compa", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bnr/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T20:39:59", "published_display": "17 Jun 2026 20:39", "sentiment": "negative", "sentiment_pct": 33, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Biotech Ltd (BNR) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Burning Rock Biotech Ltd (BNR) stock information, focusing on its dividend history and stock split events. It indicates that the company has not distributed any dividends in the past five years. However, it lists several \"Merger\" type stock sp", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bnr/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T19:39:59", "published_display": "17 Jun 2026 19:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why These High-Flying Stocks Came Back To Earth", "summary": "Shares of several U.S.-traded Chinese small- and midcap companies \u2013 Here Group, Zepp Health, Burning Rock Biotech, and So-Young International \u2013 saw meteoric rises last year but have since given back most of their gains. This phenomenon, which bears resemblances to speculative \"me", "url": "https://www.benzinga.com/Opinion/26/06/53163365/why-these-high-flying-stocks-came-back-to-earth", "source_name": "Benzinga", "published_at": "2026-06-12T12:38:51", "published_display": "12 Jun 2026 12:38", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Scheduled For June 9, 2026", "summary": "This article lists companies scheduled to report earnings on June 9, 2026. It details earnings per share and revenue estimates for companies reporting both before and after the bell, including Nathan's Famous, Burning Rock Biotech, Titan Machinery, Academy Sports, Casey's General", "url": "https://www.sahmcapital.com/news/content/earnings-scheduled-for-june-9-2026-2026-06-09", "source_name": "Sahm", "published_at": "2026-06-12T04:14:51", "published_display": "12 Jun 2026 04:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Biotech Posts Lower Q1 2026 Revenue as Shift to In-Hospital Testing Weighs on Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgJBVV95cUxOUjB1OUVaTDd1UzdjUE83aWNONWVrOHRyQnVQQmxLZ3pHNGVwaDBaa0x4Wk9kVXlYdU9hb1pIWUJsNlNWWGZtOXppb0twLUlXXzhfcGtEUVAxaE9oSWNmS3ZJZ3oxRFlHX2V6WjNFVV9XZ1dkaEFtQ2trQ1FqR29zSS1hYU5keWZiU0xtbWtPeVB0VUlRVW9VaTRLQUN4U25mWnA4MnhvU0V2TWlPbXg5YU5iTlZBVklCMmMwT3FGNEVyUExzQVo4SFZlWU1wYW9VTDUzRVBnZzVNbmZVdWw3ZGpRTkEtV05fYUZPa2tEYXdPN2c4bFltalY0TkF4ZVpINWMtbnBiSU5PSEd5T2c?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Q1 2026 revenue falls 18.9% to RMB107.9 million", "summary": "Burning Rock Biotech reported an unchanged net loss per share of $(0.20) for Q1 2026, as sales decreased by 14.67% to $15.649 million. This revenue decline was primarily due to lower performance in its central laboratory, in-hospital, and pharma R&D channels. Despite a 14.0% redu", "url": "https://scanx.trade/stock-market-news/companies/burning-rock-q1-2026-revenue-falls-18-9-to-rmb107-9-million/42548659", "source_name": "scanx.trade", "published_at": "2026-06-09T13:11:27", "published_display": "09 Jun 2026 13:11", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock reports 19% decline in Q1 2026 revenue", "summary": "Burning Rock Biotech experienced an 18.9% decline in Q1 2026 revenue, totaling RMB107.9 million, due to lower volumes in diagnostic testing and pharmaceutical services. Despite cost controls that reduced operating expenses by 14%, the company's net loss widened to RMB17.5 million", "url": "https://grafa.com/en/news/united-states/burning-rock-bnr-q1-2026-earnings-revenue-decline", "source_name": "grafa.com", "published_at": "2026-06-09T12:04:04", "published_display": "09 Jun 2026 12:04", "sentiment": "negative", "sentiment_pct": 28, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer test firm Burning Rock posts Q1 sales drop, wider loss", "summary": "Burning Rock (NASDAQ: BNR) reported a significant decline in Q1 2026 revenues to RMB107.9 million, an 18.9% year-over-year decrease, with all segments experiencing a drop. Despite a 14.0% reduction in operating expenses, the company's net loss widened to RMB17.5 million. This qua", "url": "https://www.stocktitan.net/news/BNR/burning-rock-reports-first-quarter-2026-financial-qu2np4zeb13d.html", "source_name": "Stock Titan", "published_at": "2026-06-09T11:10:04", "published_display": "09 Jun 2026 11:10", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Reports First Quarter 2026 Financial Results", "summary": "Burning Rock Biotech Limited announced its financial results for the first quarter of 2026, reporting revenues of RMB107.9 million, an 18.9% decrease year-over-year. The decrease was primarily due to declines in central laboratory business and pharma research and development serv", "url": "https://www.globenewswire.com/news-release/2026/06/09/3308663/0/en/burning-rock-reports-first-quarter-2026-financial-results.html", "source_name": "GlobeNewswire", "published_at": "2026-06-09T10:10:03", "published_display": "09 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock (NASDAQ: BNR) posts Q1 2026 loss as revenue declines", "summary": "Burning Rock Biotech (NASDAQ: BNR) reported a significant revenue decline and widened net loss for Q1 2026. Revenues fell 18.9% year-over-year to RMB107.9 million (US$15.6 million), while the net loss increased to RMB17.5 million (US$2.5 million). Despite efforts to control opera", "url": "https://www.stocktitan.net/sec-filings/BNR/6-k-burning-rock-biotech-ltd-current-report-foreign-issuer-e407b2d34caf.html", "source_name": "Stock Titan", "published_at": "2026-06-09T10:10:03", "published_display": "09 Jun 2026 10:10", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Biotech Q1 sales fall 14.7% to $15.6M", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQWWRPeWhXR1ZMWmZvNmVNYVlGb25RaEhvUllzQzhidHJBS210WldjM1gzSFFrZ0NhY2M3LTdKUUl2R0NUU2l4NkgzMUlmX0pxdFFjRUNyVDZLbWxNeWRZYkdlNEhuY25lT1cwNno2amdHTzZydzJwc1JhVzRQRm52TjJMeVo0NjlkcExvMUZiZlJEZWRSbWVmQk9OcG9nWnFpOF9EX3hNbTJHcEo0WWF1Y1BubjZzN2M?oc=5", "source_name": "scanx.trade", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Biotech (Nasdaq:BNR) - Stock Analysis", "summary": "Burning Rock Biotech (Nasdaq:BNR) develops and sells cancer therapy selection tests and has a market cap of US$95.7m. The company's stock has been volatile, showing a 152.5% increase over one year but a 65.13% decrease over three months. Recent developments include NMPA approval ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bnr/burning-rock-biotech", "source_name": "Simply Wall Street", "published_at": "2026-06-07T12:39:36", "published_display": "07 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Announces Founder's Purchase of Its ADSs", "summary": "Burning Rock Biotech Limited announced that its founder and CEO, Mr. Yusheng Yao, purchased 200,000 American Depositary Shares (ADSs) on the open market. This purchase reflects his confidence in the company's long-term business prospects and growth potential.", "url": "https://www.moomoo.com/news/post/67899212/burning-rock-announces-founder-s-purchase-of-its-adss", "source_name": "Moomoo", "published_at": "2026-05-29T20:39:17", "published_display": "29 May 2026 20:39", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kynam Capital (BNR) reports 1.23M ADSs, representing 13.97% stake", "summary": "Kynam Capital Management, LP, along with Kynam Capital Management GP, LLC and Yue Tang, has disclosed a beneficial ownership of 1,227,555 American Depositary Shares (ADSs) in Burning Rock Biotech Ltd (BNR), representing 13.97% of the class. This information was reported in an ame", "url": "https://www.stocktitan.net/sec-filings/BNR/schedule-13g-a-burning-rock-biotech-ltd-amended-passive-investment-di-576fe82cf2a9.html", "source_name": "Stock Titan", "published_at": "2026-05-15T19:38:55", "published_display": "15 May 2026 19:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRCM entities report ADS holdings in Burning Rock Biotech (BNR) \u2014 ~3% stakes", "summary": "CRCM-related entities have filed an amendment to a Schedule 13G/A, disclosing beneficial ownership of American Depository Shares (ADSs) in Burning Rock Biotech (BNR). These filings indicate shared dispositive power over 275,025 and 282,097 ADS equivalents, representing approximat", "url": "https://www.stocktitan.net/sec-filings/BNR/schedule-13g-a-burning-rock-biotech-ltd-amended-passive-investment-di-9412af612198.html", "source_name": "Stock Titan", "published_at": "2026-05-13T21:39:30", "published_display": "13 May 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Burning Rock Biotech Ltd. Sponsored ADR Stocks", "summary": "This article lists ETFs that invest in Burning Rock Biotech Ltd. Sponsored ADR stocks, providing details such as market value, weight, issuer, management style, expense ratio, and AUM for each fund. The purpose is to demonstrate how ETFs can make investing in such stocks more acc", "url": "https://www.tradingview.com/symbols/NASDAQ-BNR/etfs/", "source_name": "TradingView", "published_at": "2026-05-01T06:39:01", "published_display": "01 May 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Biotech | 20-F: FY2025 Annual Report", "summary": "This article provides immediate access to Burning Rock Biotech's 20-F Annual Report for Fiscal Year 2025. The content is explicitly noted as a direct document, indicating it contains the full financial and operational disclosures from the company.", "url": "https://www.moomoo.com/news/notice/307129867/burning-rock-biotech-20-f-fy2025-annual-report", "source_name": "Moomoo", "published_at": "2026-04-30T10:08:46", "published_display": "30 Apr 2026 10:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Publishes 2025 Annual Report on Form 20-F", "summary": "Burning Rock Biotech Limited announced it filed its Annual Report on Form 20-F for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission on April 28, 2026. The report is accessible on the SEC and company websites. Shareholders can request a hard copy ", "url": "https://www.sahmcapital.com/news/content/burning-rock-publishes-2025-annual-report-on-form-20-f-2026-04-28", "source_name": "Sahm", "published_at": "2026-04-28T19:09:39", "published_display": "28 Apr 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock posts 2025 Form 20-F, offers free hard copies", "summary": "Burning Rock Biotech (NASDAQ: BNR) filed its Annual Report on Form 20-F for the year ended December 31, 2025, on April 28, 2026. This filing is accessible on the SEC website and the company's investor site and includes audited consolidated financial statements. Shareholders and A", "url": "https://www.stocktitan.net/news/BNR/burning-rock-publishes-2025-annual-report-on-form-20-9ald4f420k9b.html", "source_name": "Stock Titan", "published_at": "2026-04-28T10:38:43", "published_display": "28 Apr 2026 10:38", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Announces Founder\u2019s Purchase of Its ADSs", "summary": "Burning Rock Biotech Limited announced that its founder, chairman, and CEO, Mr. Yusheng Han, purchased 31,487 of the company's ADSs for $546,603.90. This brings his total purchases across two consecutive post-earnings trading windows to 72,733 ADSs for over $1.35 million, demonst", "url": "https://www.manilatimes.net/2026/04/02/tmt-newswire/globenewswire/burning-rock-announces-founders-purchase-of-its-adss/2313260", "source_name": "The Manila Times", "published_at": "2026-04-08T22:38:53", "published_display": "08 Apr 2026 22:38", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Buying: Yusheng Han Acquires Shares of Burning Rock Biot", "summary": "Yusheng Han, a Director at Burning Rock Biotech Ltd (BNR), purchased 314,870 shares of the company on March 31, 2026, increasing his total holdings to 17,672,676 shares. This transaction follows a pattern of insider buying with 1 insider buy and 0 sells over the past year for BNR", "url": "https://www.gurufocus.com/news/8768378/insider-buying-yusheng-han-acquires-shares-of-burning-rock-biotech-ltd-bnr?mobile=true", "source_name": "GuruFocus", "published_at": "2026-04-02T18:13:08", "published_display": "02 Apr 2026 18:13", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Biotech (NASDAQ:BNR) Director Purchases $5,466,143.20 in Stock", "summary": "Burning Rock Biotech (NASDAQ:BNR) Director Yusheng Han recently purchased 314,870 shares of the company's stock for over $5.4 million, increasing his total holdings to 17,672,676 shares. The transaction, disclosed on March 31st, occurred at an average price of $17.36 per share. D", "url": "https://www.marketbeat.com/instant-alerts/burning-rock-biotech-nasdaqbnr-director-purchases-546614320-in-stock-2026-04-02/", "source_name": "MarketBeat", "published_at": "2026-04-02T15:10:44", "published_display": "02 Apr 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Han Yusheng adds 314,870 Burning Rock Biotech (BNR) shares", "summary": "Burning Rock Biotech Ltd Director Han Yusheng acquired 314,870 shares through an open-market purchase at a weighted average price of $17.36 per share. This transaction, totaling over $5.4 million, significantly increases his direct holdings to 17,672,676 shares, signaling strong ", "url": "https://www.stocktitan.net/sec-filings/BNR/form-4-burning-rock-biotech-ltd-insider-trading-activity-22e6195d9566.html", "source_name": "Stock Titan", "published_at": "2026-04-02T11:10:44", "published_display": "02 Apr 2026 11:10", "sentiment": "positive", "sentiment_pct": 87, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock CEO purchases $546,604 in company shares By Investing.com", "summary": "Burning Rock Biotech Limited's CEO, Yusheng Han, has purchased 31,487 American Depositary Shares (ADSs) for over $546,000 in open market transactions. This recent acquisition, combined with a previous one, brings his total purchases to 72,733 ADSs worth more than $1.35 million. T", "url": "https://in.investing.com/news/company-news/burning-rock-ceo-purchases-546604-in-company-shares-93CH-5320868", "source_name": "Investing.com India", "published_at": "2026-04-02T11:10:44", "published_display": "02 Apr 2026 11:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Biotech (BNR) Expected to Announce Earnings on Tuesday", "summary": "Burning Rock Biotech (BNR) is set to announce its Q4 2025 earnings on Tuesday, March 31st, with analysts expecting a loss of ($2.2875) per share on revenue of $19.20 million. The company's stock has recently traded down, and it faces negative financial metrics and an average \"Sel", "url": "https://www.marketbeat.com/instant-alerts/burning-rock-biotech-bnr-expected-to-announce-earnings-on-tuesday-2026-03-29/", "source_name": "MarketBeat", "published_at": "2026-03-29T18:09:29", "published_display": "29 Mar 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Biotech (BNR) Loss Reduction Trend Tests Bearish Profitability Concerns", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Reports Unaudited Fourth Quarter and Full Year 2025 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxQRU1aSzh2ZlU0a1dybXFNV2tzTUtjWEF2ODhLMU9CSFZQYnhUb0M1LU1YNjZyZ214OHZzLWF3UVdfbld2bFJzdE9CVTdsVXZ4MmhpYS15aUoxMmZvUXNBdE9oWXQ0cWlZYXpzMDM2bWJ0RWZSZHVXcXlweUYtSlZCZzhoMVV5VG1LRmhn?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Biotech (BNR) Stock Price, News & Analysis $BNR", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWEFVX3lxTE1qTXZXdUhSVE1HWDVoelREWldtZTVuUUhuWVh2VjZPd2MtcHpBWHdPX1pkYVRfVXRYa3pxWWVLeEU0S1U4SjZaeVNxVjN5R3F5QS1FU3JROEQ?oc=5", "source_name": "MarketBeat", "published_at": "2020-09-16T04:13:20+00:00", "published_display": "16 Sep 2020 04:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Burning Rock Biotech Ltd (BNR) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Burning Rock Biotech Ltd (BNR), detailing its current price momentum score, support and resistance levels, and indicator and moving average readings. It highlights that BNR's stock is trading between resistance at 14.77 and support at", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bnr/technical", "source_name": "TradingKey", "published_at": "2026-06-19T05:09:22", "published_display": "19 Jun 2026 05:09", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Biotech Ltd (BNR) Institutional Confidence", "summary": "Burning Rock Biotech Ltd (BNR) currently has an institutional shareholding score of 3.00, placing it 56th out of 76 in the Healthcare Providers & Services industry. The institutional shareholding proportion is 45.78%, showing a 1.67% decrease quarter-over-quarter. James Simons is", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bnr/sentiment", "source_name": "TradingKey", "published_at": "2026-06-19T04:39:44", "published_display": "19 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Biotech Ltd (BNR) Financial Health: Profitability & Balance Sheet Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTFBhQTNRa3V6M0Vfcnk3R0ttN1BoeEhOOTI5Y1I2aldLbHJrQUV5YTAtekxXYXJkV09pRTQ5WjRzeURQUTYtYm8wa1Z3U0RHN2l4X0tQSFYySHN4Q0s4U0JJWXl3TnZKYkRKN3NEbDFRQ20zMllyZ2VjWg?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T16:14:40+00:00", "published_display": "18 Jun 2026 16:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Biotech Ltd (BNR) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMidkFVX3lxTE90bXFfVktURDV1MkI5RDBGVFhfZXZrbjVxRjZ6eU5OQzAya0hsUmxhVXRRZWlQcGlobk5XT3JmTHFLcEtIc0thWWF5YjEzeEpMNi1qZW5kbjROeS1hWDZUWEF6Yk9MMUYxLVBsQW9ZUmdTTGpfTHc?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T16:14:08+00:00", "published_display": "18 Jun 2026 16:14", "sentiment": "negative", "sentiment_pct": 5, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Biotech Ltd (BNR) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "", "url": "https://news.google.com/rss/articles/CBMib0FVX3lxTE9LYzNrVnZWS2VBT1RENmFEcnNWS24wblpIQTZMOEszUzY2WWlVNGEtR2RCYWlmTDdPd0czX3QyNExYQWdrUnd2bGNHRGJFOVhITG1kbXlZTWZ0eDVCT3JicmNCNl9aSGlPN0dIVkExQQ?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T20:35:26+00:00", "published_display": "17 Jun 2026 20:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Biotech Ltd (BNR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Burning Rock Biotech Ltd (BNR), detailing its financial performance by business segments and regional contributions for fiscal years 2018 and 2019. It notes that relevant data for these periods have not yet been disclosed by the compa", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bnr/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T20:39:59", "published_display": "17 Jun 2026 20:39", "sentiment": "negative", "sentiment_pct": 33, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Biotech Ltd (BNR) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Burning Rock Biotech Ltd (BNR) stock information, focusing on its dividend history and stock split events. It indicates that the company has not distributed any dividends in the past five years. However, it lists several \"Merger\" type stock sp", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bnr/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T19:39:59", "published_display": "17 Jun 2026 19:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why These High-Flying Stocks Came Back To Earth", "summary": "Shares of several U.S.-traded Chinese small- and midcap companies \u2013 Here Group, Zepp Health, Burning Rock Biotech, and So-Young International \u2013 saw meteoric rises last year but have since given back most of their gains. This phenomenon, which bears resemblances to speculative \"me", "url": "https://www.benzinga.com/Opinion/26/06/53163365/why-these-high-flying-stocks-came-back-to-earth", "source_name": "Benzinga", "published_at": "2026-06-12T12:38:51", "published_display": "12 Jun 2026 12:38", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Scheduled For June 9, 2026", "summary": "This article lists companies scheduled to report earnings on June 9, 2026. It details earnings per share and revenue estimates for companies reporting both before and after the bell, including Nathan's Famous, Burning Rock Biotech, Titan Machinery, Academy Sports, Casey's General", "url": "https://www.sahmcapital.com/news/content/earnings-scheduled-for-june-9-2026-2026-06-09", "source_name": "Sahm", "published_at": "2026-06-12T04:14:51", "published_display": "12 Jun 2026 04:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Biotech Posts Lower Q1 2026 Revenue as Shift to In-Hospital Testing Weighs on Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgJBVV95cUxOUjB1OUVaTDd1UzdjUE83aWNONWVrOHRyQnVQQmxLZ3pHNGVwaDBaa0x4Wk9kVXlYdU9hb1pIWUJsNlNWWGZtOXppb0twLUlXXzhfcGtEUVAxaE9oSWNmS3ZJZ3oxRFlHX2V6WjNFVV9XZ1dkaEFtQ2trQ1FqR29zSS1hYU5keWZiU0xtbWtPeVB0VUlRVW9VaTRLQUN4U25mWnA4MnhvU0V2TWlPbXg5YU5iTlZBVklCMmMwT3FGNEVyUExzQVo4SFZlWU1wYW9VTDUzRVBnZzVNbmZVdWw3ZGpRTkEtV05fYUZPa2tEYXdPN2c4bFltalY0TkF4ZVpINWMtbnBiSU5PSEd5T2c?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Q1 2026 revenue falls 18.9% to RMB107.9 million", "summary": "Burning Rock Biotech reported an unchanged net loss per share of $(0.20) for Q1 2026, as sales decreased by 14.67% to $15.649 million. This revenue decline was primarily due to lower performance in its central laboratory, in-hospital, and pharma R&D channels. Despite a 14.0% redu", "url": "https://scanx.trade/stock-market-news/companies/burning-rock-q1-2026-revenue-falls-18-9-to-rmb107-9-million/42548659", "source_name": "scanx.trade", "published_at": "2026-06-09T13:11:27", "published_display": "09 Jun 2026 13:11", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock reports 19% decline in Q1 2026 revenue", "summary": "Burning Rock Biotech experienced an 18.9% decline in Q1 2026 revenue, totaling RMB107.9 million, due to lower volumes in diagnostic testing and pharmaceutical services. Despite cost controls that reduced operating expenses by 14%, the company's net loss widened to RMB17.5 million", "url": "https://grafa.com/en/news/united-states/burning-rock-bnr-q1-2026-earnings-revenue-decline", "source_name": "grafa.com", "published_at": "2026-06-09T12:04:04", "published_display": "09 Jun 2026 12:04", "sentiment": "negative", "sentiment_pct": 28, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer test firm Burning Rock posts Q1 sales drop, wider loss", "summary": "Burning Rock (NASDAQ: BNR) reported a significant decline in Q1 2026 revenues to RMB107.9 million, an 18.9% year-over-year decrease, with all segments experiencing a drop. Despite a 14.0% reduction in operating expenses, the company's net loss widened to RMB17.5 million. This qua", "url": "https://www.stocktitan.net/news/BNR/burning-rock-reports-first-quarter-2026-financial-qu2np4zeb13d.html", "source_name": "Stock Titan", "published_at": "2026-06-09T11:10:04", "published_display": "09 Jun 2026 11:10", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Reports First Quarter 2026 Financial Results", "summary": "Burning Rock Biotech Limited announced its financial results for the first quarter of 2026, reporting revenues of RMB107.9 million, an 18.9% decrease year-over-year. The decrease was primarily due to declines in central laboratory business and pharma research and development serv", "url": "https://www.globenewswire.com/news-release/2026/06/09/3308663/0/en/burning-rock-reports-first-quarter-2026-financial-results.html", "source_name": "GlobeNewswire", "published_at": "2026-06-09T10:10:03", "published_display": "09 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock (NASDAQ: BNR) posts Q1 2026 loss as revenue declines", "summary": "Burning Rock Biotech (NASDAQ: BNR) reported a significant revenue decline and widened net loss for Q1 2026. Revenues fell 18.9% year-over-year to RMB107.9 million (US$15.6 million), while the net loss increased to RMB17.5 million (US$2.5 million). Despite efforts to control opera", "url": "https://www.stocktitan.net/sec-filings/BNR/6-k-burning-rock-biotech-ltd-current-report-foreign-issuer-e407b2d34caf.html", "source_name": "Stock Titan", "published_at": "2026-06-09T10:10:03", "published_display": "09 Jun 2026 10:10", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Biotech Q1 sales fall 14.7% to $15.6M", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQWWRPeWhXR1ZMWmZvNmVNYVlGb25RaEhvUllzQzhidHJBS210WldjM1gzSFFrZ0NhY2M3LTdKUUl2R0NUU2l4NkgzMUlmX0pxdFFjRUNyVDZLbWxNeWRZYkdlNEhuY25lT1cwNno2amdHTzZydzJwc1JhVzRQRm52TjJMeVo0NjlkcExvMUZiZlJEZWRSbWVmQk9OcG9nWnFpOF9EX3hNbTJHcEo0WWF1Y1BubjZzN2M?oc=5", "source_name": "scanx.trade", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Biotech (Nasdaq:BNR) - Stock Analysis", "summary": "Burning Rock Biotech (Nasdaq:BNR) develops and sells cancer therapy selection tests and has a market cap of US$95.7m. The company's stock has been volatile, showing a 152.5% increase over one year but a 65.13% decrease over three months. Recent developments include NMPA approval ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bnr/burning-rock-biotech", "source_name": "Simply Wall Street", "published_at": "2026-06-07T12:39:36", "published_display": "07 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Announces Founder's Purchase of Its ADSs", "summary": "Burning Rock Biotech Limited announced that its founder and CEO, Mr. Yusheng Yao, purchased 200,000 American Depositary Shares (ADSs) on the open market. This purchase reflects his confidence in the company's long-term business prospects and growth potential.", "url": "https://www.moomoo.com/news/post/67899212/burning-rock-announces-founder-s-purchase-of-its-adss", "source_name": "Moomoo", "published_at": "2026-05-29T20:39:17", "published_display": "29 May 2026 20:39", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kynam Capital (BNR) reports 1.23M ADSs, representing 13.97% stake", "summary": "Kynam Capital Management, LP, along with Kynam Capital Management GP, LLC and Yue Tang, has disclosed a beneficial ownership of 1,227,555 American Depositary Shares (ADSs) in Burning Rock Biotech Ltd (BNR), representing 13.97% of the class. This information was reported in an ame", "url": "https://www.stocktitan.net/sec-filings/BNR/schedule-13g-a-burning-rock-biotech-ltd-amended-passive-investment-di-576fe82cf2a9.html", "source_name": "Stock Titan", "published_at": "2026-05-15T19:38:55", "published_display": "15 May 2026 19:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRCM entities report ADS holdings in Burning Rock Biotech (BNR) \u2014 ~3% stakes", "summary": "CRCM-related entities have filed an amendment to a Schedule 13G/A, disclosing beneficial ownership of American Depository Shares (ADSs) in Burning Rock Biotech (BNR). These filings indicate shared dispositive power over 275,025 and 282,097 ADS equivalents, representing approximat", "url": "https://www.stocktitan.net/sec-filings/BNR/schedule-13g-a-burning-rock-biotech-ltd-amended-passive-investment-di-9412af612198.html", "source_name": "Stock Titan", "published_at": "2026-05-13T21:39:30", "published_display": "13 May 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Burning Rock Biotech Ltd. Sponsored ADR Stocks", "summary": "This article lists ETFs that invest in Burning Rock Biotech Ltd. Sponsored ADR stocks, providing details such as market value, weight, issuer, management style, expense ratio, and AUM for each fund. The purpose is to demonstrate how ETFs can make investing in such stocks more acc", "url": "https://www.tradingview.com/symbols/NASDAQ-BNR/etfs/", "source_name": "TradingView", "published_at": "2026-05-01T06:39:01", "published_display": "01 May 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Biotech | 20-F: FY2025 Annual Report", "summary": "This article provides immediate access to Burning Rock Biotech's 20-F Annual Report for Fiscal Year 2025. The content is explicitly noted as a direct document, indicating it contains the full financial and operational disclosures from the company.", "url": "https://www.moomoo.com/news/notice/307129867/burning-rock-biotech-20-f-fy2025-annual-report", "source_name": "Moomoo", "published_at": "2026-04-30T10:08:46", "published_display": "30 Apr 2026 10:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Publishes 2025 Annual Report on Form 20-F", "summary": "Burning Rock Biotech Limited announced it filed its Annual Report on Form 20-F for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission on April 28, 2026. The report is accessible on the SEC and company websites. Shareholders can request a hard copy ", "url": "https://www.sahmcapital.com/news/content/burning-rock-publishes-2025-annual-report-on-form-20-f-2026-04-28", "source_name": "Sahm", "published_at": "2026-04-28T19:09:39", "published_display": "28 Apr 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock posts 2025 Form 20-F, offers free hard copies", "summary": "Burning Rock Biotech (NASDAQ: BNR) filed its Annual Report on Form 20-F for the year ended December 31, 2025, on April 28, 2026. This filing is accessible on the SEC website and the company's investor site and includes audited consolidated financial statements. Shareholders and A", "url": "https://www.stocktitan.net/news/BNR/burning-rock-publishes-2025-annual-report-on-form-20-9ald4f420k9b.html", "source_name": "Stock Titan", "published_at": "2026-04-28T10:38:43", "published_display": "28 Apr 2026 10:38", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Announces Founder\u2019s Purchase of Its ADSs", "summary": "Burning Rock Biotech Limited announced that its founder, chairman, and CEO, Mr. Yusheng Han, purchased 31,487 of the company's ADSs for $546,603.90. This brings his total purchases across two consecutive post-earnings trading windows to 72,733 ADSs for over $1.35 million, demonst", "url": "https://www.manilatimes.net/2026/04/02/tmt-newswire/globenewswire/burning-rock-announces-founders-purchase-of-its-adss/2313260", "source_name": "The Manila Times", "published_at": "2026-04-08T22:38:53", "published_display": "08 Apr 2026 22:38", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Buying: Yusheng Han Acquires Shares of Burning Rock Biot", "summary": "Yusheng Han, a Director at Burning Rock Biotech Ltd (BNR), purchased 314,870 shares of the company on March 31, 2026, increasing his total holdings to 17,672,676 shares. This transaction follows a pattern of insider buying with 1 insider buy and 0 sells over the past year for BNR", "url": "https://www.gurufocus.com/news/8768378/insider-buying-yusheng-han-acquires-shares-of-burning-rock-biotech-ltd-bnr?mobile=true", "source_name": "GuruFocus", "published_at": "2026-04-02T18:13:08", "published_display": "02 Apr 2026 18:13", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Biotech (NASDAQ:BNR) Director Purchases $5,466,143.20 in Stock", "summary": "Burning Rock Biotech (NASDAQ:BNR) Director Yusheng Han recently purchased 314,870 shares of the company's stock for over $5.4 million, increasing his total holdings to 17,672,676 shares. The transaction, disclosed on March 31st, occurred at an average price of $17.36 per share. D", "url": "https://www.marketbeat.com/instant-alerts/burning-rock-biotech-nasdaqbnr-director-purchases-546614320-in-stock-2026-04-02/", "source_name": "MarketBeat", "published_at": "2026-04-02T15:10:44", "published_display": "02 Apr 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Han Yusheng adds 314,870 Burning Rock Biotech (BNR) shares", "summary": "Burning Rock Biotech Ltd Director Han Yusheng acquired 314,870 shares through an open-market purchase at a weighted average price of $17.36 per share. This transaction, totaling over $5.4 million, significantly increases his direct holdings to 17,672,676 shares, signaling strong ", "url": "https://www.stocktitan.net/sec-filings/BNR/form-4-burning-rock-biotech-ltd-insider-trading-activity-22e6195d9566.html", "source_name": "Stock Titan", "published_at": "2026-04-02T11:10:44", "published_display": "02 Apr 2026 11:10", "sentiment": "positive", "sentiment_pct": 87, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock CEO purchases $546,604 in company shares By Investing.com", "summary": "Burning Rock Biotech Limited's CEO, Yusheng Han, has purchased 31,487 American Depositary Shares (ADSs) for over $546,000 in open market transactions. This recent acquisition, combined with a previous one, brings his total purchases to 72,733 ADSs worth more than $1.35 million. T", "url": "https://in.investing.com/news/company-news/burning-rock-ceo-purchases-546604-in-company-shares-93CH-5320868", "source_name": "Investing.com India", "published_at": "2026-04-02T11:10:44", "published_display": "02 Apr 2026 11:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Biotech (BNR) Expected to Announce Earnings on Tuesday", "summary": "Burning Rock Biotech (BNR) is set to announce its Q4 2025 earnings on Tuesday, March 31st, with analysts expecting a loss of ($2.2875) per share on revenue of $19.20 million. The company's stock has recently traded down, and it faces negative financial metrics and an average \"Sel", "url": "https://www.marketbeat.com/instant-alerts/burning-rock-biotech-bnr-expected-to-announce-earnings-on-tuesday-2026-03-29/", "source_name": "MarketBeat", "published_at": "2026-03-29T18:09:29", "published_display": "29 Mar 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Biotech (BNR) Loss Reduction Trend Tests Bearish Profitability Concerns", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOUGlGSFZnZGFselJySXdDUlNYa0ZYbGZLbnRtYTlNY0pJWXdmY2FHVW11MVA4OHh1czV1V0NSbkNkUXhhalcxemlxSEljVkR6eTJ2RGxYNHAxSEhPOU5GQ1FjUFhvdUJoYzNIUWlqQk10LUpuNmZXc0F2UFYxYTNLNndCVF9SWEdCbm9rQ1IwbnBFOEo4MnFRd18xMzJOMzh6X3NhX3IyRkk2LXplazhXV0xyM2lqTkJsRUZmRGdraWJ4MFJCdGxYTVBnX3RmWWFlWG01bFVLNFRudUZyeTlwa3NTM0hGNzjSAewBQVVfeXFMT3BDazlpVktYcUxGVDd3MG10WG1keksyUlBCdWE1T1lQYXJvbWRPMHJTYzZOUDhHV1FWbDJsT1c5Z3VsUnZMUlVUbDFyNEZqNkRpQlFOSFpPaDRiU094ZGZIYmZjVkFVM0hTNTNNNUlxU0FLQkcwNnV0YWQ5ZDFhS2p3bzVBSWJCTkxSekk4ZGVjbVVURUZkcFhhODVLX3VvWGhmdFI1NmI2VzhHRUotdmwxa0RRWk1yaThIaF9mXzFUbDA0c29ONTgyaFVKOS1oWWYtMGZaSVZPaGwwT1QwZ0lDb2lINGk3eGNaNkg?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Reports Unaudited Fourth Quarter and Full Year 2025 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxQRU1aSzh2ZlU0a1dybXFNV2tzTUtjWEF2ODhLMU9CSFZQYnhUb0M1LU1YNjZyZ214OHZzLWF3UVdfbld2bFJzdE9CVTdsVXZ4MmhpYS15aUoxMmZvUXNBdE9oWXQ0cWlZYXpzMDM2bWJ0RWZSZHVXcXlweUYtSlZCZzhoMVV5VG1LRmhn?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Burning Rock Biotech (BNR) Stock Price, News & Analysis $BNR", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWEFVX3lxTE1qTXZXdUhSVE1HWDVoelREWldtZTVuUUhuWVh2VjZPd2MtcHpBWHdPX1pkYVRfVXRYa3pxWWVLeEU0S1U4SjZaeVNxVjN5R3F5QS1FU3JROEQ?oc=5", "source_name": "MarketBeat", "published_at": "2020-09-16T04:13:20+00:00", "published_display": "16 Sep 2020 04:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 86, "total_relevant": 33, "sentiment_summary": {"positive": 5, "negative": 12, "neutral": 16, "score": 46, "total": 33, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 11.0, "count": 20}, {"event": "earnings", "label": "Earnings", "weight": 4.95, "count": 9}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 5, "negative_events": 12}, "market_context": {"has_market_context": true, "latest_close": 7.25, "latest_week": "2026-06-19", "one_week_move": -15.6, "four_week_move": -50.0, "twelve_week_move": -55.7, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.532941, "market_dynamics_buy_signal": false, "relative_strength": -60.388015, "fair_value_gap": -28.9, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 32.5876, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-15.6% over one week, -50.0% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 63, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingKey", "count": 7}, {"label": "Stock Titan", "count": 6}, {"label": "MarketBeat", "count": 3}, {"label": "Sahm", "count": 2}, {"label": "scanx.trade", "count": 2}, {"label": "Moomoo", "count": 2}, {"label": "Benzinga", "count": 1}, {"label": "The Globe and Mail", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 33}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 20}, {"label": "Earnings", "count": 9}, {"label": "Deals and strategy", "count": 3}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "46/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "33", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-15.6% over one week, -50.0% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "Burning Rock Biotech Ltd (BNR) Technical Analysis: Support, Resistance, Indicators & Moving Averages"}], "updated_at": "2026-06-22T16:28:46.302798+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}